June S. Almenoff
Independent DirectorDr. June S. Almenoff, M.D., Ph.D., F.A.C.P., is Independent Director of Actinium Pharmaceuticals, Inc. from November 1, 2024. Dr. Almenoff served as Chief Medical Officer at RedHill Biopharma Ltd from 2021 until May 2024. She had been Chief Scientific Officer of RedHill Biopharma Ltd. since May 28, 2019 until 2021. Dr. Almenoff serves as an Independent Director at Tenax Therapeutics Inc. since February 25, 2021. She serves as Director at inSoma Bio, Inc. Dr. Almenoff served as the Chief Operating Officer and Chief Medical Officer of 9 Meters Biopharma, Inc. (formerly known as Innovate Biopharmaceuticals, Inc.) since March 13, 2018 until November 16, 2018. Since 2015, Dr. Almenoff served as the Executive Chairman of RDD Pharma, Ltd (now 9 Meters Biopharma, Inc.) until 2018. Prior to March 2015, Dr. Almenoff, served as an independent biopharma consultant, including serving as a consultant for Innovate beginning in January 2018. Dr. Almenoff is a Consulting Professor of Medicine at Duke University Medical Center and was previously a Faculty. Dr. Almenoff is an accomplished biopharma executive with lots of senior leadership experience. From December 2014 until June 2016, she was an Executive-in-Residence and consultant at Hatteras Venture Partners. She is an accomplished executive with experience in the pharmaceutical industry. She served as the Chief Medical Officer and President of Furiex Pharmaceuticals, Inc. since March 16, 2010 until October 2014 and served as its Principal Executive Officer. She served as Vice President of Clinical Safety & Pharma Covigilance Organization at GSK, where she served on its senior governing medical boards and managed a diverse therapeutic portfolio supporting numerous regulatory approvals. Dr. Almenoff led or contributed to numerous regulatory submissions and product approvals. Dr. Almenoff has strong expertise in translational medicine, clinical development, commercial strategy and business development and has previously advised biotech boards and management in these areas. During her career at GSK, she served as a Vice President in the R&D/Clinical Safety organization and worked in the area of scientific licensing. She worked in GSK's licensing group, where she led the scientific licensing, leading the research and development diligence process for the acquisition of Stiefel Laboratories and established a licensing program fora drug development unit. She served at GlaxoSmithKline (GSK) from 1997 to 2010, where she held positions of increasing responsibility, including Vice President of the clinical safety and pharmacovigilance organization. She had been Member of Advisory Board at RedHill Biopharma Ltd. since January 2019 until 2019. She serves as a Member of The Boards of Valanbio. She served as Independent Director of Avalo Therapeutics, Inc. since November 10, 2021 until 2025. She served as an Independent Director of TiGenix NV from September 22, 2016 until 2018. She was a Director at Furiex Pharmaceuticals, Inc. since March 2010 until October 2014. She served as a Director of Brainstorm Cell Therapeutics Inc. from February 26, 2017 to December 18, 2023. She served as Independent Director of Ohr Pharmaceutical, Inc. since May 22, 2013. She served as Director of NeuBase Therapeutics, Inc. She was a Member of Advisory Board at RedHill Biopharma Ltd. since February 2016 until March 2018. She is a director-advisor of inSoma Bio, Inc. She serves on the Boards of The Council for Entrepreneurial Development. Dr. Almenoff also chaired a PhRMA-FDA working group and was the Lead Author on its influential position paper. She also serves on the Investment Advisory Board of the Harrington Discovery Institute since 2015 (Case Western Univ.). She served as Director of Kurome Therapeutics, Inc., since 2020. She has authored close to 60 publications and one pending patent. She is a Board-Certified Fellow of the American College of Physicians with clinical practice experience. She led the development of several pioneering systems for minimizing risk in early- and late-stage drug development; these have been widely implemented by pharmaceutical companies and regulatory agencies and were recognized with numerous awards including the Wall Street Journal Technology Innovation Award. Dr. Almenoff holds her B.A. cum laude from Smith College. She completed Post-Graduate Medical Training at Stanford University Medical Center and served on the faculty of Duke University School of Medicine. She graduated with AOA honors from the M.D.-Ph.D. program at the Icahn (Mt. Sinai) School of Medicine and completed a residency in Internal Medicine and a Fellowship in Infectious Diseases at Stanford University Medical Center.
Positions
- Company NameTenax Therapeutics, Inc.Stock CodeTENXPositionIndependent DirectorColleagues
- CTChristopher T. GiordanoCEO, President & Director
- GTGerald T. ProehlIndependent Chairman
- TAThomas A. McGauleyPrincipal Financial Officer & Principal Accounting Officer
- SRStuart RichChief Medical Officer & Director
- TRThomas R. StaabChief Financial Officer
- DRDoug RandallChief Business Officer
- SJSanjiv J. ShahChairman of Scientific Advisory Board
